The company is one of a handful developing a more “selective” URAT1 inhibitor, an approach that’s seen as a way to improve upon existing therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback